Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease

Clinical Rheumatology

Volumn 27, Issue 3, 2008, Pages 373-375

  Direskeneli, H ^a   Ergun, T ^b   Yavuz, S ^a   Hamuryudan, V ^c   Eksioglu Demiralp, E ^b  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Behcet's disease; T cells; Thalidomide

Indexed keywords

CD11B ANTIGEN; CD16 ANTIGEN; CD18 ANTIGEN; CD28 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD56 ANTIGEN; HERMES ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEHCET DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY INTERVENTION; ERYTHEMA NODOSUM; FEMALE; GAMMA DELTA T LYMPHOCYTE; HEADACHE; HUMAN; MALE; MEMORY T LYMPHOCYTE; NATURAL KILLER T CELL; PRIORITY JOURNAL; REMISSION; T LYMPHOCYTE; TREATMENT DURATION; UROGENITAL ULCER; UVEITIS; DRUG EFFECT; IMMUNOLOGY; IMMUNOPHENOTYPING; NATURAL KILLER CELL; T LYMPHOCYTE SUBPOPULATION;

ADULT; BEHCET SYNDROME; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; MALE; T-LYMPHOCYTE SUBSETS; THALIDOMIDE;

EID: 41949118969     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0786-8     Document Type: Article

References (20)

1. H Direskeneli 2001 Review: Behçet's disease: infectious etiology, new auto-antigens and HLA-B51 Ann Rheum Dis 82 996 1002 10.1136/ard.60.11.996 (Pubitemid 32990034)
2. T Saylan I Saltik 1982 Thalidomide in the treatment of Behcet's syndrome Arch Dermatol 118 536 7103519 10.1001/archderm.118.8.536 1:STN:280: Bi2B2MrkvVI%3D
3. MH Hamza 1986 Treatment of Behcet's disease with thalidomide Clin Rheumatol 5 365 371 3780143 10.1007/BF02054255 1:STN:280:BiiD2M3lt1A%3D
4. JL Jorizzo FC Schmalstieg AR Solomon Jr T Cavallo RS Taylor 3rd HB Rudloff EJ Schmalstieg JC Daniels 1986 Thalidomide effects in Behcet's syndrome and pustular vasculitis Arch Intern Med 146 878 881 3963978 10.1001/archinte. 146.5.878 1:STN:280:BimC1crosFU%3D (Pubitemid 16116664)
5. V Hamuryudan C Mat S Saip Y Ozyazgan A Siva S Yurdakul, et al. 1998 Thalidomide in the treatment of the mucocutaneous lesions of the Behçet's syndrome. A randomized, double-blind, placebo-controlled trial Ann Intern Med 128 443 450 9499327 1:CAS:528:DyaK1cXitFeltLg%3D
6. R Knight 2005 IMiDs: a novel class of immunomodulators Semin Oncol 32 Suppl 5 S24 S30 16085014 10.1053/j.seminoncol.2005.06.018 1:CAS:528: DC%2BD2MXhtVWjt7%2FO
7. L Calabrese AB Fleischer 2000 Thalidomide: current and potential clinical applications AM J Med 108 487 495 10781782 10.1016/S0002-9343(99)00408-8 1:CAS:528:DC%2BD3cXislaqsbk%3D (Pubitemid 30214201)
8. EP Sampaio EN Sarno R Galilly, et al. 1991 Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocyte J Exp Med 173 699 703 1997652 10.1084/jem.173.3.699 1:CAS:528:DyaK3MXhsFKku70%3D
9. SM McHugh IR Rifkin J Deighton, et al. 1995 The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen and antigen-stimulated human peripheral blood mononuclear cell cultures Clin Exp Immunol 99 160 167 7851006 1:CAS:528:DyaK2MXktl2hs7g%3D
10. LG Corral PAJ Haslett GW Muller R Chen LM Wong CJ Ocampo, et al. 1999 Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α J Immunol 163 380 386 10384139 1:CAS:528:DyaK1MXkt1SisLw%3D
11. International Study Group for Behçet's Disease 1990 Criteria for diagnosis of Behçet's disease Lancet 335 1078 1080
12. AL Moriera EP Sampaio A Zmuidzinas, et al. 1993 Thalidomide exerts its inhibitory action on tumor necrosis factor-α by enhancing m-RNA degradation J Exp Med 177 1675 1680 10.1084/jem.177.6.1675
13. H Geitz S Handt K Zwingerberger 1996 Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade Immunopharmacology 131 213 221 10.1016/0162-3109(95)00050-X (Pubitemid 26122649)
14. 2, but not that activated by ceramide, lipopolysaccharides or phorbol ester J Immunol 168 2644 2651 11884428 1:CAS:528:DC%2BD38XitFSksbY%3D
15. M Todaro M Zerilli G Triolo, et al. 2005 NF-κB protects Behcet's disease T cells against CD95-induced apoptosis up-regulating anti-apoptotic proteins Arthritis Rheum 52 2179 2191 15986355 10.1002/art.21145 1:CAS:528:DC%2BD2MXnsl2gtL4%3D (Pubitemid 40994341)
16. ES Lee YA Kim HJ Kwon D Bang S Lee S Sohn 2004 Thalidomide upregulates macrophage inflammatory protein-1α in a herpes simplex virus-induced Behcet's disease-like animal model Arch Dermatol Res 296 175 181 15290170 1:CAS:528:DC%2BD2cXotVOhtL4%3D
17. PA Haslett P Roche CR Butlin, et al. 2005 Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation J Infect Dis 192 2045 2053 16288366 10.1086/498216 1:CAS:528: DC%2BD28XhvFansQ%3D%3D (Pubitemid 41779200)
18. I Estrada-G A Garibay-Escobar A Nunez-Vazquez, et al. 2004 Evidence that thalidomide modifies the immune response of patients suffering from actinic prurigo Int J Dermatol 43 893 897 15569010 10.1111/j.1365-4632.2004.02274.x 1:CAS:528:DC%2BD2MXjslGgtg%3D%3D (Pubitemid 39642314)
19. A Kibaroglu E Eksioglu-Demiralp T Akoglu H Direskeneli 2004 T and NK cell subset changes with microbial extracts and human HSP60-derived peptides in Behcet's disease Clin Exp Rheumatol 22 Suppl 34 S59 S63 15515788 1:STN:280:DC%2BD2crksVWmuw%3D%3D
20. J Freysdottir S Lau F Fortune 1999 Gamma-delta T cells in Behcet's disease (BD) and recurrent aphthous stomatitis (RAS) Clin Exp Immunol 118 451 457 10594567 10.1046/j.1365-2249.1999.01069.x 1:CAS:528:DC%2BD3cXivFOgtQ%3D%3D